---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-073072"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:44:49.202923+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics annual meeting: all 9 directors elected, auditor ratified, say-on-pay approved

## Summary
- All nine director nominees elected with 89.8M-90.8M votes for and 1.5M-2.4M withheld.
- Ratification of WithumSmithBrown as auditor passed: 128.6M for, 2.4M against.
- Advisory say-on-pay approved: 87.8M for, 3.7M against, 0.7M abstentions.
- Board amended bylaws effective June 11, 2024, updating advance notice and California code compliance.
- Bylaw changes include Rule 14a-19 compliance requirement and electronic meeting provisions.

## SEC filing metadata
- accession: 0000950170-24-073072
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017024073072/0000950170-24-073072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017024073072/lctx-20240613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-073072
- JSON: https://secwatch.observer/filing/0000950170-24-073072.json
- Plain text: https://secwatch.observer/filing/0000950170-24-073072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.